Etanercept or Methotrexate Withdrawal in Rheumatoid Arthritis Patients in Sustained Remission.

ABSTRACT:

Objective

Patients with rheumatoid arthritis (RA) in whom remission is achieved following combination therapy with methotrexate plus etanercept face an ongoing medication burden. This study was undertaken to investigate whether sustained remission achieved on combination therapy can be maintained with either methotrexate or etanercept monotherapy, as assessed following discontinuation of one or the other medication from the combination.

Methods

Of the 371 adult patients with RA who received combination therapy with methotrexate plus etanercept, remission (defined as a Simplified Disease Activity Index [SDAI] score of ≤3.3) was sustained in 253 patients through a 24-week open-label period. These 253 patients then entered a 48-week, double-blind period and were randomized to r

SUBMITTER: Curtis JR 

PROVIDER: S-EPMC8251940 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature